FilingReader Intelligence

Zhongsheng Pharma subsidiary secures European patent for antiviral drug

July 17, 2025 at 10:50 AM UTCBy FilingReader AI

Guangdong Zhongsheng Pharmaceutical announced its subsidiary Guangdong Zhongsheng Ruichuang Biotechnology received a European patent for an anti-influenza virus compound.

The patent covers Anglabivir, an innovative drug approved in May 2025 for treating adult patients with simple type A influenza. The compound patents have already been granted in numerous countries including China, the United States, Japan, South Korea, Australia, Canada, Brazil, and others.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

News Alerts

Get instant email alerts when Guangdong Zhongsheng Pharmaceutical publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →